---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000004"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:32:04.524984+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Novocure completes enrollment in Phase 3 TRIDENT trial for newly diagnosed glioblastoma; data expected 2026

## Summary
- Final patient enrolled in global Phase 3 TRIDENT trial (950 patients) evaluating Optune Gio concurrent with radiation + temozolomide for newly diagnosed GBM.
- Patients randomized to TTFields + TMZ + radiation vs TMZ + radiation for 6 weeks, then all receive standard care (TTFields + maintenance TMZ).
- Primary endpoint is overall survival; secondary endpoints include PFS, safety, quality of life, and radiological response.
- Top-line data from the trial is anticipated in 2026; enrollment began in December 2020.

## SEC filing metadata
- accession: 0001645113-24-000004
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000004/0001645113-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000004/nvcr-20240109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000004
- JSON: https://secwatch.observer/filing/0001645113-24-000004.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.